Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym001 in RhD-positive ITP
NCT00718692Phase 2Completed
- Sponsor
- Symphogen
- Start
- Jul 2008
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of Rozrolimupab in immune thrombocytopenic purpura (ITP), sponsored by Symphogen. Started Jul 2008; status: completed.
02
Drugs
Rozrolimupab
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00718692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718692.